Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin’s lymphoma—a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group

2005 ◽  
Vol 63 (3) ◽  
pp. 860-865 ◽  
Author(s):  
Hans Theodor Eich ◽  
Uwe Haverkamp ◽  
Andreas Engert ◽  
Martin Kocher ◽  
Roman Skripnitchenko ◽  
...  
Keyword(s):  
Acute Toxicity ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Study Group ◽  
German Hodgkin Study Group ◽  
Biophysical Analysis ◽  
Extended Field ◽  
Involved Field ◽  
Involved Field Radiotherapy

Hodgkin's Lymphoma in Adolescents Treated With Adult Protocols: A Report From the German Hodgkin Study Group

2009 ◽  
Vol 27 (36) ◽  
pp. 6079-6085 ◽  
Author(s):  
Dennis A. Eichenauer ◽  
Henning Bredenfeld ◽  
Heinz Haverkamp ◽  
Horst Müller ◽  
Jeremy Franklin ◽  
...  
Keyword(s):  
Risk Factors ◽  
Young Adults ◽  
Hodgkin’S Lymphoma ◽  
Age Groups ◽  
Hodgkin's Lymphoma ◽  
Study Group ◽  
Cox Regression Analysis ◽  
German Hodgkin Study Group ◽  
Study Protocols ◽  
Adolescent Patients

PurposeThe standard of care for adolescent patients with Hodgkin's lymphoma (HL) is undefined, particularly the choice between pediatric and adult protocols. Thus, we compared risk factors and outcome of adolescents and young adults treated within study protocols of the German Hodgkin Study Group (GHSG).Patients and MethodsThree thousand seven hundred eighty-five patients treated within the GHSG studies HD4 to HD9 were analyzed; 557 patients were adolescents age 15 to 20 years, and 3,228 patients were young adults age 21 to 45 years.ResultsLarge mediastinal mass and involvement of three or more lymph node areas were more frequent in adolescents (P < .001). The incidence of other risk factors did not differ significantly between age groups. With a median observation time of 81 months for freedom from treatment failure (FFTF) and 85 months for overall survival (OS), log-rank test showed no significant differences between age groups regarding FFTF (P = .305) and a superior OS (P = .008) for adolescents. Six-year estimates for FFTF and OS were 80% and 94%, respectively, for adolescents and 80% and 91%, respectively, for young adults. After adjustment for other predictive factors, Cox regression analysis revealed age as a significant predictor for OS (P = .004), with a higher mortality risk for young adults. Secondary malignancies were more common in young adults (P = .037).ConclusionOutcome of adolescent and young adult patients treated within GHSG study protocols is comparable. These data suggest that adult treatment protocols exhibit a safe and effective treatment option for adolescent patients with HL. However, longer follow-up, including assessment of late toxicity, is necessary for final conclusions.

Sign in / Sign up

Export Citation Format

Share Document